Blaze Bioscience
Seattle, US · Founded 2010 · Delaware corporation · 2 known investors
Find your way into Blaze Bioscience
316 people in our graph share verified history with the Blaze Bioscience team — schools, employers, funds. One of them is your warm intro.
Andrewunlockedknows Steven R. Daly · together at University of Washington (overlapped)
×3knows the team · via University of Washington
×8knows the team · via UW Foster School of Business
Blaze Bioscience develops peptide-based fluorescent imaging agents and imaging systems that give surgeons real-time visualization of tumor tissue during cancer surgery. Its technology serves surgical oncology, with breast-conserving surgery and pediatric/adult brain cancer as lead indications.
Founders & leadership
Blaze Bioscience was founded in 2010 by James M. Olson.
JM
James M. OlsonFounder
SR
Steven R. DalyinPresident and CEOSteven R. Daly has 25 years of experience in biotechnology and medical device development, with involvement in program execution across 14 clinical studies and regulatory submissions, along with strategic partnerships and corporate development work with pharmaceutical companies.
LR
Ludmila R. LobanovaExecutive
JN
Julia NovakExecutive
HL
Heather L. FranklinNamed on SEC filing
DM
Dennis M MillerNamed on SEC filing
Board
JC
James C. TowneBoard director
LP
Lawrence Patrick HughesBoard director
JK
Jan K. OhrstromBoard director
ME
Mary Ellen HughesBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$108.7M disclosed across 10 rounds · 2013–2024
▶$15MraisedOct 2024 · 6 investors · BiotechnologyRule 506(b)
▶$15MraisedOct 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jan K. OhrstromDirector
- Steven R. DalyExecutive Officer, Director
- James C. TowneExecutive Officer, Director
- Lawrence Patrick HughesDirector
- Heather L. FranklinDirector
- Ludmila R. LobanovaExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedOct 2024 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedOct 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jan K. OhrstromDirector
- Heather L. FranklinDirector
- Ludmila R. LobanovaExecutive Officer
- Steven R. DalyExecutive Officer, Director
- James C. TowneExecutive Officer, Director
- Lawrence Patrick HughesDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.1MraisedOct 2024 · 2 investors · BiotechnologyRule 506(b)
▶$8.1MraisedOct 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Heather L. FranklinDirector
- Steven R. DalyExecutive Officer, Director
- Lawrence Patrick HughesDirector
- James C. TowneExecutive Officer, Director
- Ludmila R. LobanovaExecutive Officer
- Jan K. OhrstromDirector
- Offering amount
- $20M
- Amount sold
- $8.1M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedOct 2024 · 3 investors · BiotechnologyRule 506(b)
▶$25MraisedOct 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven R. DalyExecutive Officer, Director
- Heather L. FranklinDirector
- Jan K. OhrstromDirector
- James C. TowneExecutive Officer, Director
- Ludmila R. LobanovaExecutive Officer
- Lawrence Patrick HughesDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedApr 2020 · 38 investors · BiotechnologyRule 506(b)
▶$20.2MraisedApr 2020 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Claudia JochheimExecutive Officer
- Jan Koch OhrstromDirector
- Dennis MillerExecutive Officer
- Mary Ellen HughesDirector
- Ludmila LobanovaExecutive Officer
- Heather FranklinExecutive Officer, Director
- James Cameron TowneDirector
- Offering amount
- $25.2M
- Amount sold
- $20.2M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMay 2018 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedMay 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAN OHRSTROMDirector
- CLAUDIA JOCHHEIMExecutive Officer
- DENNIS MILLERExecutive Officer
- MARY ELLEN HUGHESDirector
- HEATHER FRANKLINExecutive Officer, Director
- LUDMILA LOBANOVAExecutive Officer
- JAMES C. TOWNEDirector
- Offering amount
- $5M
- Amount sold
- $3M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.1MraisedOct 2017 · 32 investors · BiotechnologyRule 506(b)
▶$16.1MraisedOct 2017 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- LUDMILA LOBANOVAExecutive Officer
- MARY ELLEN HUGHESDirector
- HEATHER FRANKLINExecutive Officer, Director
- JAN OHRSTROMDirector
- JAMES C. TOWNEDirector
- DENNIS MILLERExecutive Officer
- Offering amount
- $18.1M
- Amount sold
- $16.1M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$554KraisedJun 2017 · 5 investors · BiotechnologyRule 506(b)
▶$554KraisedJun 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAMES C. TOWNEDirector
- MARY ELLEN HUGHESDirector
- LUDMILA LOBANOVAExecutive Officer
- JAN OHRSTROMDirector
- DENNIS MILLERExecutive Officer
- HEATHER FRANKLINExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $554K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Precision BioSciences13 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Castle Biosciences10 shared keywordsCastle Biosciences develops genomic diagnostic tests that use a patient's molecular biology to inform disease management and treatment decisions. Its tests serve healthcare providers and patients across multiple clinical focus areas to guide diagnosis, treatment, and follow-up care.
Pillar Biosciences10 shared keywordsPillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics. Its oncoReveal portfolio of RUO and IVD oncology panels covers solid tumors, hematologic cancers, and liquid biopsy, aiming to deliver faster, lower-cost genomic testing for precision medicine.
Life Biosciences9 shared keywordsLongevity company with diversified therapies to extend healthy human lifespan
Companies competing with Blaze Bioscience for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $248.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Blaze Bioscience do?
- Blaze Bioscience develops peptide-based fluorescent imaging agents and imaging systems that give surgeons real-time visualization of tumor tissue during cancer surgery. Its technology serves surgical oncology, with breast-conserving surgery and pediatric/adult brain cancer as lead indications.
- Who founded Blaze Bioscience?
- Blaze Bioscience was founded by James M. Olson in 2010.
- Who are Blaze Bioscience's investors?
- Blaze Bioscience's investors include Keiretsu Forum, Keiretsu Capital.
- How much funding has Blaze Bioscience raised?
- Blaze Bioscience has disclosed $108.7M raised across 10 rounds.
- Where is Blaze Bioscience headquartered?
- Blaze Bioscience is headquartered in Seattle, US.